RB1 and non-small cell lung carcinoma: Studies have indicated that NSCLC patients with concurrent EGFR/RB1/TP53 mutations are more prone to transform into SCLC (31), especially those with a high frequency of AID/APOBEC mutations and genomic amplifications.